DMT1 mutation: Response of anemia to darbepoetin administration and implications for iron homeostasis [7]

Blood

Volumn 108, Issue 1, 2006, Pages 404-405

  Pospisilova, Dagmar ^a   Mims, Martha P ^a   Nemeth, Elizabeta ^a   Ganz, Tomas ^a   Prchal, Josef T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; BLOOD SAMPLING; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; GENE MUTATION; HEMOSTASIS; HUMAN; HYPOXIA; IRON ABSORPTION; LETTER; PRIORITY JOURNAL; URINALYSIS;

EID: 33745601679     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-003962     Document Type: Letter

References (10)

1. Mims MP, Guan Y, Pospisilova D, et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood. 2005;105:1337-1342.
2. Gunshin H, Jin J, Fujiwara Y, Andrews NC. Analysis of the E399D mutation in SLC11A2. Blood. 2005;106:2221-2222.
3. Priwitzerova M, Nie G, Sheftel AD, Pospisilova D, Divoky V, Ponka P. Functional consequences of the human DMT1 (SLC11A2) mutation on protein expression and iron uptake. Blood. 2005;106:3985-3987.
4. Priwitzerova M, Pospisilova D, Prchal JT, et al. Severe hypochromic microcytic anemia caused by a congenital defect of the iron transport pathway in erythroid cells. Blood. 2004;103:3991-3992.
5. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute phase protein. Blood. 2003;101:2461-2463.
6. Iolascon A, d'Apolito M, Servedio V, Cimmino F, Piga A, Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1. Blood. 2006;107:349-354.
7. Beaumont C, Delaunay J, Hetet G, De Montalembert M, Grandchamp B, Tchernia GJ. Two new human DMT1 mutations in a compound heterozygous patient with microcytic anemia and low iron stores. Blood. Prepublished on January 26, 2006, as DOI 10.1182/blood-2005-10-4269.
8. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood. 2005;106:2196-2199.
9. Nicolas G, Chauvet C, Viatte, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037-1044.
10. Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood. 2005;105:4103-4104.